NCT01650428 - Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 10, 2018

Study Completion Date

February 14, 2019

Conditions

Rectal Cancer

Interventions

BIOLOGICAL

Bevacizumab

5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).

DRUG

Irinotecan

165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6

DRUG

Oxaliplatin

165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6

DRUG

5-Fluorouracil

3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6

Trial Locations (11)

Unknown

Blackpool Victoria Hospital, Blackpool

Beatson West of Scotland Cancer Centre, Glasgow

Charing Cross Hospital, London

Guy's and St Thomas' Hospital, London

Hammersmith Hospital, London

North MiddlesexHospital, London

Royal Marsden Hospitals NHS Foundation Trust, London

UCLH, London

Mount Vernon Hospital, Middlesex

Wexham Park Hospital, Slough

Lister Hospital, Stevenage